Longitudinal evaluation of anti-SARS-CoV-2 neutralizing antibody levels in 3-dose homologous (mRNA-1273- mRNA-1273- BNT162b2) vaccinated kidney transplant population: 18-month follow-up.

ABSTRACT:

Objectives

This study aimed to assess the immune response to a three-dose primary series of COVID-19 vaccination in kidney transplant recipients (KTRs), a population vulnerable to infection due to immunosuppression.

Methods

This study was a longitudinal evaluation of neutralizing antibody (nAB) dynamics in 43 KTRs in a lower-middle-income setting receiving a three-dose homologous (messenger RNA [mRNA]-1273-mRNA-1273- BNT162b2) vaccination against COVID-19. Samples were obtained at time points (TP) as follows: TP0, pre-vaccination; TP1, 1-month post-first dose (mRNA-1273); TP2, 1-month post-second dose (mRNA-1273); TP3, 4 months post-second dose; TP4, 2 weeks post-third dose (BNT162b2); TP5, 5 months post-third dose; and TP6, 12 months post-third dose. Anti-SARS-CoV-2 nAB wer

SUBMITTER: Karunathilake KRP 

PROVIDER: S-EPMC12549382 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature